Plaque Psoriasis: Epidemiology Forecast to 2027

Plaque Psoriasis: Epidemiology Forecast to 2027

Summary

Plaque psoriasis is a chronic immune-mediated skin disease characterized by red, flaky patches that are itchy and sometimes painful. Psoriatic plaques are formed due to an increased production of skin cells; normally the process to make and replace skin cells takes three to four weeks, but in psoriasis patients the process takes only a few days. Plaque psoriasis, referred to as psoriasis in this report, is usually diagnosed by the look and distribution of plaques, and sometimes a small biopsy of the skin may be sent for analysis under the microscope.

GlobalData epidemiologists forecast an increase in the one-year diagnosed prevalent cases of plaque psoriasis in the 7MM, from 16,030,747 cases in 2017 to 18,413,814 cases in 2027, at an AGR of 1.49% during the forecast period. Plaque psoriasis is not a life-threatening condition, but does have a significant impact on the patients’ quality of life. Plaque psoriasis is often accompanied by one or more comorbidities, and frequently patients are stigmatized and excluded from social participation. Other burdens associated with plaque psoriasis are socioeconomic ones, as patients can face elevated economic burden for treatment expenses and income lost due to disability, depending on the severity of the condition.

To ensure comparability of the prevalence proportions reported in the 7MM, GlobalData epidemiologists used uniform diagnostic criteria for case ascertainment in all markets.

Scope

- The Plaque Psoriasis Epidemiology Report provides an overview of the risk factors and global trends of plaque psoriasis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report provides an overview of the risk factors, comorbidities, and global and historical trends for plaque psoriasis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the one-year diagnosed prevalent cases of plaque psoriasis segmented by sex and age (beginning at 18 years and ending at ≥80 years) in these markets. Additionally the one-year diagnosed prevalent cases of plaque psoriasis are segmented into cases with psoriatic arthritis (PsA) and by severity.
- The plaque psoriasis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Plaque Psoriasis Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global plaque psoriasis market.
- Quantify patient populations in the global plaque psoriasis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for plaque psoriasis therapeutics in each of the markets covered.
- Understand magnitude of plaque psoriasis segmentation by severity.